Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | LCK | P06239 | 4/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769494 | 0.86 | JAK3 (0.44) | JAK3LCKTTKPROKR1MAP3K14 | |
| SCHEMBL15769392 | 0.86 | LRRK2 (0.32) | JAK3HRH3PLK1RORC | |
| SCHEMBL15770073 | 0.84 | LCK (0.35) | JAK3LCKHRH3PLK1 | |
| SCHEMBL15769708 | 0.84 | ALK (0.35) | JAK3SIGMAR1 | |
| SCHEMBL15769944 | 0.84 | LRRK2 (0.31) | HRH3PLK1 | |
| SCHEMBL15769752 | 0.83 | LRRK2 (0.41) | JAK3PLK1RORC | |
| SCHEMBL15769433 | 0.82 | LRRK2 (0.38) | PLK1 | |
| SCHEMBL15770107 | 0.81 | JAK3 (0.35) | JAK3LCKTTK | |
| SCHEMBL15769429 | 0.79 | JAK3 (0.45) | JAK3LCKTTKSIGMAR1 | |
| SCHEMBL15769448 | 0.78 | APP (0.33) | JAK3MAP3K14HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | claimed |
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | JAK3 572/4885LCK 213/4885TTK 267/4885 |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | JAK3 572/4885LCK 213/4885TTK 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.